Actively Recruiting
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
Led by University of Liverpool · Updated on 2025-09-04
290
Participants Needed
13
Research Sites
413 weeks
Total Duration
On this page
Sponsors
U
University of Liverpool
Lead Sponsor
B
Bangor University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.
CONDITIONS
Official Title
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients attending Accident and Emergency or admitted via GP with a new diagnosis of acute pancreatitis confirmed by at least two of the following: typical continuous upper abdominal pain; amylase and/or lipase three or more times the upper limit of normal; characteristic abdominal imaging findings if done urgently
- Ability to start trial treatment within 36 hours of hospital admission allowing 120 minutes for medication preparation
- Appropriate consent obtained from the patient or their legal representative
You will not qualify if you...
- Age under 18 or over 85 years
- Bodyweight over 200 kilograms
- Previous acute pancreatitis within last 30 days or chronic pancreatitis
- Multiple sclerosis, systemic vasculitis, Guillain-Barré syndrome, or other demyelinating disorders
- Known epilepsy
- Moderate to severe heart failure or coronary disease (NYHA III/IV)
- Severe respiratory diseases including cystic fibrosis, severe asthma, or severe COPD
- Use of home oxygen or mechanical ventilation
- Jaundice or known advanced liver disease
- Active cancer with chemotherapy or radiotherapy ongoing or completed in last 6 months
- Known hematological malignancy
- Cancer receiving palliative care
- Known or suspected infection including COVID-19 at acute pancreatitis onset
- History or household contact with tuberculosis or opportunistic infections
- History of infective hepatitis
- Rare diseases or metabolic disorders increasing infection risk including SCID or homozygous sickle cell disease
- Receipt of live vaccine or infectious agent within one month before admission
- Use of immunosuppressive or biologic therapy within one month before admission
- Known hypersensitivity to infliximab, its components, or murine proteins
- Pregnancy or lactation at admission
- Females of childbearing potential not agreeing to use contraception for 6 months after infusion
- Participation in investigational medicinal product study within last three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZN
Actively Recruiting
2
University Hospital of Wales
Cardiff, Cardiff, United Kingdom, CF14 4XW
Not Yet Recruiting
3
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom, TR1 3LJ
Not Yet Recruiting
4
Royal Devon and Exeter Hospital
Exeter, Devon, United Kingdom, EX2 5DW
Not Yet Recruiting
5
University College London Hospital
London, Greater London, United Kingdom, NW1 2BU
Actively Recruiting
6
St Mary's Hospital
London, Greater London, United Kingdom, W2 1NY
Suspended
7
Charing Cross Hospital
London, Greater London, United Kingdom, W6 8RF
Suspended
8
Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom, L7 8XP
Actively Recruiting
9
Aintree University Hospital
Liverpool, Merseyside, United Kingdom, L9 7AL
Actively Recruiting
10
Whiston Hospital
Whiston, Merseyside, United Kingdom, L35 5DR
Actively Recruiting
11
Queen's Medical Centre
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Actively Recruiting
12
John Radcliffe Hospital
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Actively Recruiting
13
St James's University Hospital
Leeds, West Yorkshire, United Kingdom, LS9 7TF
Not Yet Recruiting
Research Team
M
Matt Smyth, BSc
CONTACT
C
Catherine E Spowart, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here